Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of IDP-120 Gel in Acne Vulgaris
NCT03664739Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Mar 2020
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of benzoyl peroxide + sulfur and tretinoin in acne vulgaris (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Absolute Change in Mean Lesion Counts at 12 weeks and Percentage of Subjects Achieving EGSS Success at 12 weeks. Started Dec 2018; status: completed.
02
Drugs
benzoyl peroxide + sulfurtretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03664739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664739.